Have a feature idea you'd love to see implemented?
Let us know!
CLPT ClearPoint Neuro Inc
Price (delayed)
$15.705
Market cap
$433.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.68
Enterprise value
$415.34M
ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of
Highlights
CLPT's debt has shrunk by 74% YoY and by 73% QoQ
The gross profit has grown by 42% YoY and by 9% from the previous quarter
The quick ratio has soared by 55% from the previous quarter but it has contracted by 30% YoY
The equity has grown by 20% YoY but it has contracted by 10% from the previous quarter
Key stats
What are the main financial stats of CLPT
Market
Valuations
Earnings
Shares outstanding
27.58M
Market cap
$433.22M
Enterprise value
$415.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
14.94
Price to sales (P/S)
14.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.65
Revenue
$30.43M
Gross profit
$18.37M
Net income
-$18.15M
EBIT
-$18.34M
EBITDA
-$16.48M
Free cash flow
-$9.08M
Per share
Balance sheet
Liquidity
EPS
-$0.68
EPS diluted
-$0.68
Free cash flow per share
-$0.33
Book value per share
$1.05
Revenue per share
$1.1
TBVPS
$1.43
Total assets
$40.19M
Total liabilities
$11.19M
Debt
$3.69M
Equity
$29M
Working capital
$26.78M
Debt to equity
0.13
Current ratio
4.54
Quick ratio
3.37
Net debt/EBITDA
1.08
Margins
Efficiency
Dividend
EBITDA margin
-54.2%
Gross margin
60.4%
Net margin
-59.6%
Operating margin
-61.9%
Return on assets
-38.4%
Return on equity
-62.1%
Return on invested capital
-104.3%
Return on capital employed
-56.2%
Return on sales
-60.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLPT stock price
How has the ClearPoint Neuro stock price performed over time
Intraday
7.35%
1 week
-3.89%
1 month
32.7%
1 year
139.41%
YTD
131.3%
QTD
40.1%
Financial performance
How have ClearPoint Neuro's revenue and profit performed over time
Revenue
$30.43M
Gross profit
$18.37M
Operating income
-$18.85M
Net income
-$18.15M
Gross margin
60.4%
Net margin
-59.6%
The gross profit has grown by 42% YoY and by 9% from the previous quarter
CLPT's net margin is up by 39% YoY and by 7% QoQ
ClearPoint Neuro's operating margin has increased by 38% YoY and by 6% from the previous quarter
ClearPoint Neuro's revenue has increased by 36% YoY and by 8% from the previous quarter
Growth
What is ClearPoint Neuro's growth rate over time
Valuation
What is ClearPoint Neuro stock price valuation
P/E
N/A
P/B
14.94
P/S
14.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.65
ClearPoint Neuro's EPS has increased by 24% YoY and by 2.9% from the previous quarter
The P/B is 110% above the last 4 quarters average of 7.1 but 66% below the 5-year quarterly average of 43.5
The equity has grown by 20% YoY but it has contracted by 10% from the previous quarter
The price to sales (P/S) is 95% higher than the last 4 quarters average of 7.3 and 17% higher than the 5-year quarterly average of 12.2
ClearPoint Neuro's revenue has increased by 36% YoY and by 8% from the previous quarter
Efficiency
How efficient is ClearPoint Neuro business performance
ClearPoint Neuro's return on invested capital has decreased by 41% YoY and by 19% QoQ
ClearPoint Neuro's ROS has increased by 39% YoY and by 7% from the previous quarter
The return on equity has grown by 14% year-on-year and by 3.3% since the previous quarter
CLPT's ROA is up by 13% YoY but it is down by 2.9% from the previous quarter
Dividends
What is CLPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLPT.
Financial health
How did ClearPoint Neuro financials performed over time
The current ratio has soared by 63% from the previous quarter but it has contracted by 32% YoY
The quick ratio has soared by 55% from the previous quarter but it has contracted by 30% YoY
CLPT's debt is 87% lower than its equity
The debt to equity has dropped by 78% year-on-year and by 70% since the previous quarter
CLPT's debt has shrunk by 74% YoY and by 73% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.